Head-to-head evidence
AV-101 vs Blixeprodil
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Major Depressive Disorder
Shared mechanism: NMDA receptor · full Major Depressive Disorder pipeline
AV-101
Developed by VistaGen Therapeutics
NCT02484456 · Phase 2 · completed
Nineteen participants were randomized to receive AV-101 and placebo in a double-blind crossover design. The primary clinical depression endpoint was not statistically significant at the reported time points; for example, the day-0 comparison was 20.22 with AV-101 versus 20.56 with placebo (p=0.68), and the day-13 comparison was 21.52 versus 19.69 (p=0.26).
Blixeprodil
Developed by Gilgamesh Pharmaceuticals
NCT06309277 · Phase 2 · completed
The study was randomized, quadruple-blind, placebo-controlled, and included 46 participants, but the primary endpoint was treatment-emergent adverse-event incidence rather than an efficacy endpoint. The registry reports adverse-event counts but no statistical comparison for this primary endpoint, so whether it was met is unclear; the depression-rating result was a statistically significant secondary finding.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: AV-101's landscape · Blixeprodil's landscape